Non-alcoholic Fatty Liver Disease

16 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Non-alcoholic Fatty Liver Disease
Treatment and conditionWhere it standsTrials
Berberine ursodeoxycholate for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
DR10624 Injection for non-alcoholic fatty liver diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ECC0509 for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ECC0509 + ECC4703 for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ECC4703 for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Efruxifermin for non-alcoholic fatty liver diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Empagliflozin for non-alcoholic fatty liver diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Food Security Screening & Referral Program for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
HSK31679 for non-alcoholic fatty liver diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
HU6 for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pegargiminase for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PolyPill for non-alcoholic fatty liver diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide for non-alcoholic fatty liver diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
SNP-610 for non-alcoholic fatty liver diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Standard Soy Milk for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Survodutide for non-alcoholic fatty liver diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1